



Realtime Data Use-Case for Earlier Strategic Transactions, with Evidence of Success

The largest pharma company in the world just transacted with a small, privately held therapeutics company equipped with advanced technologies from Prevail InfoWorks *prior* to their Phase 2 study completion. They received \$1.5 billion. At the study start, a stellar list of strategics were engaged and allowed access to a realtime review of data as the study was ongoing, pitting the strategics against one another throughout the study. An elegant auction process ensued. This was as opposed to the traditional way of initiating a DD process *after* study conclusion, when often the data is considered inadequate or not the right data to reach the high bar of a pharma transaction.

The Single Interface™ (SI) from Prevail InfoWorks captures the steady stream of data being generated, allowing it to be vetted in realtime. The data flows into the central repository of the SI where the data is treated with protocol rules and algorithms, automatically reconciled then redistributed in appropriate, blinded, role-based views. When you are working with the advanced technologies from Prevail InfoWorks, you are working with a tool purpose-built for driving exits.

That sponsor company isn't the first or the only to use this approach. Others have used it for investor due diligence and even negotiating for less onerous requirements from the FDA. Take advantage of the agency's willingness to do real time data review in their new initiative. Prevail has a track record of FDA product approvals, \$12b in cash-on-hand licensing deals, IPOs/uplistings, and three other major pharma exits.